Treace Medical Concepts, Inc. provided revenue guidance for the full year 2022. The company expects revenue for the full year 2022 to range from $125 million to $130 million, which represents approximately 32% to 38% growth over the company's 2021 revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.16 USD | +2.38% | +3.20% | -59.53% |
05-17 | North American Morning Briefing : The "Everything -2- | DJ |
05-16 | UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.53% | 320M | |
+75.35% | 12.55B | |
-23.01% | 7.51B | |
+8.35% | 6.74B | |
+14.40% | 5.47B | |
-14.85% | 4.89B | |
+32.74% | 4.74B | |
-23.06% | 2.9B | |
+55.06% | 2.49B | |
+0.25% | 1.99B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Provides Revenue Guidance for the Full Year 2022